Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders

Bibliography

• Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-40
   PubMed Web of Science ®Google Scholar
• Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Ann Intern Med 2004;140:867-73
   PubMed Web of Science ®Google Scholar
• Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-702
   PubMed Web of Science ®Google Scholar
• Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin k antagonists-the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:204S-233S
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C. New anticoagulants. Semin Thromb Hemost 2006;32:793-802
   PubMed Web of Science ®Google Scholar
• Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008;99:208-14
   PubMed Web of Science ®Google Scholar
• Hérault JP, Bernat A, Roye F, et al. Pharmacokinetics of new synthetic heparin mimetics. Thromb Haemost 2002;87:985-9
   PubMed Web of Science ®Google Scholar
• Hérault JP, Gaich C, Bono F, et al. The structure of synthetic oligosaccharides in relation to factor IXa inhibition. Thromb Haemost 2002;88:432-5
   PubMed Web of Science ®Google Scholar
• Hérault JP, Perrin B, Jongbloet C, et al. Effect of factor Xa inhibitors on the platelet-derived microparticles procoagulant activity in vitro and in vivo in rats. Thromb Haemost 2000;84:668-74
   PubMed Web of Science ®Google Scholar
• Olson ST, Swanson R, Raub-Segall EI, et al. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin. Thromb Haemost 2004;92:929-39
   PubMed Web of Science ®Google Scholar
• Gouin-Thibault I, Dingler E, Maris FA, Samama MM. In vitro interaction of the pentasaccharide idraparinux (SanOrg34006) with unfractionated heparin. J Thromb Haemost 2003;1:2054-6
   PubMed Web of Science ®Google Scholar
• Faaij RA, Burggraaf J, Schoemaker RC, et al. A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of subcutaneous SANORG 34006 in healthy male and female elderly volunteers [abstract 1547]. Thromb Haemost 1999;(Suppl)
   Google Scholar
• Faaij RA, Burggraaf J, Schoemaker RC, et al. A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of SANORG 34006 in healthy young male volunteers [abstract 2709]. Thromb Haemost 1999;(Suppl)
   Google Scholar
• Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Hematol 2004;124:653-8
   PubMed Web of Science ®Google Scholar
• PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost 2004;2:47-53
   PubMed Web of Science ®Google Scholar
• van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007;357:1094-104
   PubMed Web of Science ®Google Scholar
• Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:401S-428S
   PubMedGoogle Scholar
• van Gogh Investigators. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007;357:1105-12
   PubMed Web of Science ®Google Scholar
• The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomized, open-label, non-inferiority trial. Lancet 2008;371:315-21
   PubMed Web of Science ®Google Scholar
• Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). Available from: http://clinicaltrials.gov/ct2/show/NCT00311090?term=NCT00311090&rank=1
   Google Scholar
• Clinical study assessing SSR126517E injections once-weekly in pulmonary embolism therapeutic approach (CASSIOPEA). Available from: http://clinicaltrials.gov/ct2/show/NCT00345618?term=NCT00345618&rank=1
   Google Scholar
• Evaluation of weekly subcutaneous biotinylated idraparinux versus oral adjusted-dose warfarin to prevent stroke and systemic thromboembolic events in patients with atrial fibrillation (BOREALIS-AF). Available from: http://clinicaltrials.gov/ct2/show/NCT00580216?term=NCT00580216&rank=1
   Google Scholar
• Savelieva I. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med 2007;39:371-91
   PubMed Web of Science ®Google Scholar